Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080080
Status:
COMPLETED
Last Update Posted:
2007-06-08
First Post:
2004-03-23
Brief Title:
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Sponsor:
Point Therapeutics
Organization:
Point Therapeutics
Study Overview
Official Title:
Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the antitumor activity response rate time to tumor progression survival and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer NSCLC who have failed a prior platinum-containing regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None